Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity
Models, Molecular
0301 basic medicine
Neurons/cytology/drug effects
Estrogen Receptor alpha/agonists/biosynthesis
Estrogen Receptor beta/agonists/biosynthesis
Molecular Conformation
Apoptosis
Cell Proliferation/drug effects
Structure-Activity Relationship
03 medical and health sciences
Cell Line, Tumor
Animals
Estrogen Receptor beta
Humans
Cell Proliferation
Neurons
Estrogen Receptor alpha
Dehydroepiandrosterone
Apoptosis/*drug effects
Neuroprotective Agents/adverse effects/*chemical synthesis/pharmacology
Rats
3. Good health
Neuroprotective Agents
synthesis/pharmacology
Dehydroepiandrosterone/adverse effects/*analogs & derivatives/*chemical
DOI:
10.1021/jm900468p
Publication Date:
2009-11-05T06:43:08Z
AUTHORS (12)
ABSTRACT
DHEA analogues with modifications at positions C3 or C17 were synthesized and evaluated for neuroprotective activity against the neural-crest-derived PC12 cell model of serum deprivation-induced apoptosis. The most potent compounds were the spiro-epoxy derivatives 17beta-spiro[5-androstene-17,2'-oxiran]-3beta-ol (20), (20S)-3beta,21-dihydroxy-17beta,20-epoxy-5-pregnene (23), and (20R)-3beta,21-dihydroxy-17alpha,20-epoxy-5-pregnene (27) with IC(50) values of 0.19 +/- 0.01, 99.0 +/- 4.6, and 6.4 +/- 0.3 nM, respectively. Analogues 20, 23, and 27, up to the micromolar range of concentrations, were unable to activate estrogen receptor alpha and beta (ERalpha and ERbeta) or to interfere with ER-dependent gene expression significantly. In addition, they were unable to stimulate the growth of Ishikawa, MCF-7, and LNCaP cells. Our results suggest that the spiro-epoxyneurosteroid derivatives 20, 23, and 27 may prove to be lead molecules for the synthesis of novel neuroprotective agents.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (96)
CITATIONS (52)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....